Drug intelligence / Profile preview

Artemune

Development stage: Unknown
Lead developer: Jena Herbals
Administration: Oral

Overview

Artemune is an herbal supplement developed and manufactured by Jena Herbals Limited, a Uganda-based company specializing in botanical medicines. The product is primarily derived from *Artemisia annua* (Sweet Wormwood) and is marketed for its immunomodulatory and antiviral properties. It gained prominence in East Africa during the COVID-19 pandemic, receiving approval from the Uganda National Drug Authority (NDA) as a supportive treatment for viral infections and general immune system enhancement. The therapeutic effects of Artemune are attributed to the diverse phytochemical profile of *Artemisia annua*, which includes artemisinin, flavonoids, and essential oils that collectively contribute to anti-inflammatory and antioxidant activities.

Brand names: Artemune
Other names: Artemisia annua extract

Beyond the preview

Go deeper on Artemune.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artemune.

Explore the full profile